1-8 of 8
Jean-François Viallard, MD-PhD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Ruxolitinib Therapy in Myelofibrosis: Analysis of 241 Patients Treated in Compassionate Use (French “ATU” program) by the French Intergroup of Myeloproliferative Neoplasms (FIM).

Annalisa Andreoli, MD, Jerome Rey, MD, Charles Dauriac, MD, Raoul Herbrecht, MD, Franck E. Nicolini, MD, PhD, Christian Recher, MD, PhD, Philippe Rousselot, MD, PhD, Jacques Delaunay, MD, Bernard Drenou, MD, PhD, Dana Ranta, MD, Laurence Legros, MD, PhD, Martine Delain, MD, Pascale Cony-Makhoul, MD, Jean-François Viallard, MD, PhD, Sorin Visanica, MD, Sophie Lefort, MD, Brigitte Dupriez, MD, Valérie Coiteux, MD, Denis Guyotat, MD, Borhane Slama, MD, Khaled Benabed, MD, Jean-Loup Demory, MD, Stephane Giraudier, MD, PhD, Damien Roos-Weil, MD, Laurence Sanhes, MD, Anne Quinquenel, MD, Pascal Lenain, MD, Valérie Ugo, MD, PhD, Jean-Jacques Kiladjian, MD, PhD, Lydia Roy, MD
Journal: Blood
Blood (2012) 120 (21): 2841.
https://doi.org/10.1182/blood.V120.21.2841.2841
Published: 2012
Journal Articles

FCGR3A V/F 158 Polymorphism Is Not Associated with Response to Rituximab in adult's Immune Thrombocytopenia

Constance Guillaud Danis, France Noizat-Pirenne, Christophe Tournamille, Olivier Fain, Jean-François Viallard, MD, PhD, Bertrand Godeau, MD, Marc Michel
Journal: Blood
Blood (2012) 120 (21): 1090.
https://doi.org/10.1182/blood.V120.21.1090.1090
Published: 2012
Journal Articles

Romiplostim for the Treatment of Adults with Primary Immune Thrombocytopenia (ITP) in Routine Clinical Practice – Interim Results From a Large, European, Observational Study

Dominik Selleslag, Ann Janssens, Hans Wadenvik, Michael Steurer, MD, Philippe Quittet, MD, Georgia Kaiafa, Tomas Kozak, MD, Helen Papadaki, Jean-François Viallard, MD, PhD, Kerry Dillingham, Georg Kreuzbauer, MD
Journal: Blood
Blood (2012) 120 (21): 3316.
https://doi.org/10.1182/blood.V120.21.3316.3316
Published: 2012
Journal Articles

Switching From Romiplostim to Eltrombopag or Vice Versa for Immune Thrombocytopenia: Efficacy and Safety in 46 Patients

Mehdi Khellaf, Jean-François Viallard, MD, PhD, Mohamed Hamidou, Stephane Cheze, Francois Lefrere, Olivier Fain, Sylvain Audia, M.D., Ph.D., Fabrice Jardin, MD, PhD, Emmanuel Gyan, MD, PhD, jean Marc Durand, Corinne Haioun, Philippe Bierling, MD, Marc Michel, Bertrand Godeau, MD
Journal: Blood
Blood (2012) 120 (21): 4651.
https://doi.org/10.1182/blood.V120.21.4651.4651
Published: 2012
Journal Articles

Intrinsic Impairment of Platelet Production in Persistent/Chronic ITP

Etienne Riviere, Jean-François Viallard, MD, PhD, Juliana Vieira Dias, PhD, Anne Cecile Pons, Thierry Couffinhal, MD, PhD, Jean-Luc Pellegrin, MD, PhD, Chloe James, MD, PhD
Journal: Blood
Blood (2012) 120 (21): 624.
https://doi.org/10.1182/blood.V120.21.624.624
Published: 2012
Journal Articles

Use of Rituximab in a Study Comparing the Thrombopoietin Mimetic Romiplostim with Standard of Care (SOC) in Patients with Immune Thrombocytopenia (ITP),

Jeffrey Wasser, MD, Ralph Vincent V. Boccia, MD, Roger M. Lyons, MD, Romeo Mandanas, Ingrid Pabinger, Marc Michel IV, Jean-François Viallard, MD-PhD, Xuena Wang, PhD, Richard Lizambri, MD
Journal: Blood
Blood (2011) 118 (21): 3282.
https://doi.org/10.1182/blood.V118.21.3282.3282
Published: 2011
Journal Articles

A Multicenter Case-Control Prospective Study to Assess the Risk of Immune Thrombocytopenia (ITP) Associated with Vaccines in Adults Using the PGRx-ITP Registry

Lamiae Grimaldi-Bensouda, Marc Michel, Jean-François Viallard, MD-PhD, Daniel Adoue, Nadine Magy-Bertrand, Medhi Khellaf, Maya Hacini, MD, Olivier Fain, Anne-Sophie Morin, Philippe Quittet, MD, Brigitte Pan-Petesch, Bernard Bonnotte, Nathalie Chalumeau-Costeadoat, Michel Ruel, Pamela Leighton, Elodie Aubrun, Annick Alperovitch, Lucien Abenhaim, Bertrand Godeau, MD
Journal: Blood
Blood (2011) 118 (21): 1169.
https://doi.org/10.1182/blood.V118.21.1169.1169
Published: 2011
Journal Articles

Pegylated Interferon Alpha-2a Therapy for Patients with High Risk Essential Thrombocytemia: a Retrospective Analysis on 59 Patients.On Behalf of the French Intergroup of Myeloproliferative Disorders (FIM)

Lydia Roy, MD, Jean Christophe Ianotto, MD, Joelle Guilhot, MBci, Emmanuel Raffoux, MD, Emmanuel Gyan, MD, PhD, Benoit de Renzis, MD, Laurence Legros, MD, Jean-François Viallard, MD-PhD, Françoise Boyer, MD, Cony Makhoul, MD, Franck E Nicolini, MD, PhD, Jean Gunecht, MD, Stephane Giraudier, MD-PhD
Journal: Blood
Blood (2010) 116 (21): 1974.
https://doi.org/10.1182/blood.V116.21.1974.1974
Published: 2010